IE
TNGX icon

Israel Englander’s Tango Therapeutics TNGX Stock Holding History

Israel Englander’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,000
Closed -$230K – 6474
2025
Q2 		$230K Buy
+45,000
New +$111K ﹤0.01% 5303

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Israel Englander's TNGX Position: Q2 2026 in Review

Israel Englander increased its Tango Therapeutics (TNGX) stake by 17% in Q2 2026, buying an estimated $1.74M and bringing the position to 496,036 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1866.

Israel Englander first reported a position in TNGX in Q3 2020 and has held it in 20 quarters since. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Israel Englander held 496,036 shares of Tango Therapeutics worth $15.5M as of Q2 2026.
  • Israel Englander bought 70,392 Tango Therapeutics shares in Q2 2026, an estimated $1.74M.
  • Tango Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1866 holding.
  • Israel Englander first reported a position in Tango Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.